6667 — Mega Genomics Share Price
Last trade - 00:00Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 5.52% | ||
| Return on Equity | 4.83% | ||
| Operating Margin | 24.24% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | CNYm | 123.7 | 203.22 | 237.19 | 145.73 | 151.3 | n/a | n/a | 5.16% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | +166.4 | +20.28 | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Mega Genomics Ltd is an investment holding company primarily engaged in the provision of genetic testing and cancer screening services. The Company mainly operates it business through two segments. The Consumer Genetic Testing Services segment is engaged in providing brain health assessment package, alimentation capability assessment package, Parkinson’s disease risk assessment, whole exome sequencing package for adult and others. The Cancer Screening Services segment is engaged in providing Alzheimer’s disease screening kits, colorectal cancer screening kits, gastric cancer screening kits, lung nodule auxiliary diagnostic kits and cervical cancer screening kits. The Company mainly conducts its business in the domestic market.
Directors
- Last Annual
- December 31st, 2023
- Last Interim
- June 30th, 2024
- Incorporated
- April 22nd, 2021
- Public Since
- June 22nd, 2022
- No. of Employees
- 214
- Sector
- Healthcare Providers & Services
- Industry
- Healthcare
- Exchange
- Stock Exchange of Hong Kong Limited
- Shares in Issue
- 224,300,200
- Address
- 401 Health Work, BEIJING
- Web
- https://www.megagenomics.cn/
- Phone
- Auditors
- Ernst & Young
Upcoming Events for 6667
Similar to 6667
Adicon Holdings
Stock Exchange of Hong Kong Limited
Aidigong Maternal & Child Health
Stock Exchange of Hong Kong Limited
Arrail
Stock Exchange of Hong Kong Limited
Suzhou Basecare Medical
Stock Exchange of Hong Kong Limited
Bayzed Health
Stock Exchange of Hong Kong Limited
FAQ
As of Today at 21:59 UTC, shares in Mega Genomics are trading at HK$7.20. This share price information is delayed by 15 minutes.
Shares in Mega Genomics last closed at HK$7.20 and the price had moved by -28.14% over the past 365 days. In terms of relative price strength the Mega Genomics share price has underperformed the FTSE Developed Asia Pacific Index by -37.13% over the past year.
The overall consensus recommendation for Mega Genomics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreMega Genomics does not currently pay a dividend.
Mega Genomics does not currently pay a dividend.
Mega Genomics does not currently pay a dividend.
To buy shares in Mega Genomics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of HK$7.20, shares in Mega Genomics had a market capitalisation of .
Here are the trading details for Mega Genomics:
- Country of listing: Hong Kong
- Exchange: HKG
- Ticker Symbol: 6667
Based on an overall assessment of its quality, value and momentum Mega Genomics is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Mega Genomics. Over the past six months, its share price has underperformed the FTSE Developed Asia Pacific Index by -34.31%.
As of the last closing price of HK$7.20, shares in Mega Genomics were trading matched their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Mega Genomics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at HK$7.20.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on Mega Genomics' directors